Physician profile
Bridget C Schaefer
NPI 1801840251
$3,978.33
in general payments reported to CMS, 2019-2025
25 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $956 · 2023: $1,143 · 2024: $279 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.95 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $861.88 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $406.07 | 2021-2024 | Xolair |
| Glaxosmithkline, LLC. | $333.46 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Blueprint Medicines Corporation | $268.99 | 2023 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $258.66 | 2021-2023 | Dupixent |
| Optinose US, INC. | $257.33 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.18 | 2021-2023 | Takhzyro |
| Abbvie INC. | $211.19 | 2022-2023 | |
| Pfizer INC. | $174.72 | 2021-2024 | |
| Kaleo, INC. | $154.76 | 2021-2023 | Auvi-Q |
| Incyte Corporation | $152.97 | 2022-2023 | Opzelura |
| Genzyme Corporation | $145.34 | 2021-2023 | |
| Leo Pharma INC. | $101.32 | 2022-2023 | Adbry |
| Amgen INC. | $71.47 | 2022-2023 | Tezspire |
| Csl Behring | $60.69 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $43.41 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Octapharma USA, INC. | $42.92 | 2023-2025 | Cutaquig |
| Bio Products Laboratory USA, INC. | $35.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.34 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $28.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.70 | 2023 | Spiriva Respimat |
| Uswm, LLC | $21.00 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $19.31 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $18.26 | 2023 | Ryaltris |
| Aytu Biopharma, INC. | $16.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.